Symptom overlap in patients with upper gastrointestinal complaints in the Canadian confirmatory acid suppression test (CAST) study: Further psychometric validation of the reflux disease questionnaire

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 9, 2007, Pages 1087-1097

  Van Zanten, S V ^a   Armstrong, D ^b   Barkun, A ^c   Junghard, O ^d   White, R J ^e   Wiklund, I K ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d ASTRAZENECA R AND D   (Sweden)

^e ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; CORRELATION COEFFICIENT; CRONBACH ALPHA COEFFICIENT; DISEASE SEVERITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; STOMACH ACID; TREATMENT DURATION; TREATMENT RESPONSE; UPPER GASTROINTESTINAL TRACT; VALIDATION PROCESS;

ADULT; ANTI-ULCER AGENTS; CANADA; DYSPEPSIA; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MALE; OMEPRAZOLE; PSYCHOMETRICS; QUESTIONNAIRES;

EID: 34247172985     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03271.x     Document Type: Article

References (47)

1. Chiba N, Van Zanten SJ, Sinclair P, et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002; 324: 1012-6.
2. McCormick A, Fleming DM, Charlton J. Morbidity statistics from general practice: fourth national study 1991-1992. Office of Population Censuses and Surveys: London, 1995. Available at: http://www.statistics.gov.uk/downloads/ theme_health/MB5No3.pdf. Accessed February 28, 2005.
3. Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003; 17: 1481-91.
4. Fennerty MB. Use of antisecretory agents as a trial of therapy. Gut 2002; 50 (Suppl. 4): iv63-6.
5. Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002; 122: 1270-85.
6. Veldhuyzen van Zanten S, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Can Med Assoc J 2000; 12 (Suppl): S3-23.
7. Veldhuyzen van Zanten SJ, Bradette M, Chiba N, et al. Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Can J Gastroenterol 2005; 19: 285-303.
8. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl. 2): II37-42.
9. Westbrook JI, McIntosh JH, Talley NJ. The impact of dyspepsia definition on prevalence estimates: considerations for future researchers. Scand J Gastroenterol 2000; 35(3): 227-33.
10. Agreus L. Natural history of dyspepsia. Gut 2002; 50 (Suppl. 4): iv2-9.
11. Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45 (Suppl. 2): II69-77.
12. Sharma N, Donnellan C, Preston C, et al. A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials. Gut 2004; 53 (Suppl. 4): iv58-65.
13. Bytzer P. Assessment of reflux symptom severity: methodological options and their attributes. Gut 2004; 53 (Suppl. 4): iv28-34.
14. Talley NJ, Wiklund I. Patient reported outcomes in reflux disease: an overview of available measures. Qual Life Res 2005; 14: 21-33.
15. Wiklund IK, Junghard O, Grace E, et al. Quality of life in reflux and dyspepsia patients Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998; 583: 41-9.
16. McColl E. Best practice in symptom assessment: a review. Gut 2004; 53 (Suppl. 4): iv49-54.
17. Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 52-7.
18. Nocon M, Kulig M, Leodolter A, et al. Validation of the reflux disease questionnaire for a German population. Eur J Gastroenterol Hepatol 2005; 17: 229-33.
19. Wiklund I, Veldhuyzen van Zanten S, Armstrong D, et al. Validation of the reflux disease questionnaire (RDQ), a symptom scale for use in patients with upper gastrointestinal (GI) symptoms. International Society of Quality of Life Research: Boston, MA, 2004. Available at: http://www.isoqol.org/ 2004sympabstracts. pdf. Accessed May 25, 2005.
20. Talley NJ, Fullerton S, Junghard O., et al. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001; 96: 1998-2004.
21. Veldhuyzen Van Zanten SJ, Chiba N, Armstrong D, et al. Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials. Aliment Pharmacol Ther 2006; 23: 521-9.
22. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47: 81-7.
23. Jaeschke R, Singer J, Guyatt GH. Measurement of health status ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-15.
24. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1023-9.
25. SAS_Institute_INC. SAS version 8.02. Cary, 2001.
26. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297-334.
27. Armstrong D, Veldhuyzen van Zanten SJO, Barkun AN, Tanser L, Chakraborty B, Nevin K. Symptom response at one week to predict outcome at four weeks with esomeprazole (E) in heartburn-dominant uninvestigated dyspepsia (HBDUD) patients: the confirmatory acid suppression test (CAST) study. Gastroenterology 2003; 124 (4 Suppl. 1): A540.
28. Armstrong D, Veldhuyzen van Zanten SJO, Barkun AN, et al.. Symptom response at 1-week predicts responders at 4-weeks with esomeprazole (40 mg bid and od) in patients with uninvestigated dyspepsia. Am J Gastroenterol 2003; 98 (9 Suppl. 4): S48-9 (Abstract).
29. Hinkle DE, Jurs SG, Wiersma W. Applied statistics for the behavioural sciences, 2nd ed. Boston: Houghton Mifflin, 1988.
30. McColl E, Junghard O, Wiklund I, et al. Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients? Am J Gastroenterol 2005; 100: 11-8.
31. Haque M, Wyeth JW, Stace NH, et al. Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: a population-based study. N Z Med J 2000; 113: 178-81.
32. Guillemot F, Ducrotte P, Bueno L. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice. Gastroenterol Clin Biol 2005; 29: 243-6.
33. Shaib Y, El-Serag HB. The prevalence and risk factors of functional dyspepsia in a multiethnic population in the United States. Am J Gastroenterol 2004; 99: 2210-6.
34. Talley NJ, Piper DW. The association between non-ulcer dyspepsia and other gastrointestinal disorders. Scand J Gastroenterol 1985; 20: 896-900.
35. Mahadeva S, Raman MC, Ford AC, et al. Gastro-oesophageal reflux is more prevalent in Western dyspeptics: a prospective comparison of British and South-East Asian patients with dyspepsia. Aliment Pharmacol Ther 2005; 21: 1483-90.
36. Bytzer P, Talley NJ. Dyspepsia. Ann Intern Med 2001; 2: 815-22.
37. Vakil N, van Zanten SV, Chang L, et al. Comprehension and awareness of symptoms in women with dyspepsia. Aliment Pharmacol Ther 2005; 22: 1147-55.
38. Locke GR, Talley NJ, Weaver AL, et al. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 1994; 69: 539-47.
39. Enns MW, Larsen DK, Cox BJ. Discrepancies between self and observer ratings of depression. The relationship to demographic, clinical and personality variables. J Affect Disord 2000; 60: 33-41.
40. Wiklund I, Comerford MB, Dimenas E. The relationship between exercise tolerance and quality of life in angina pectoris. Clin Cardiol 1991; 14: 204-8.
41. Fallone CA, Guyatt GH, Armstrong D, et al. Do physicians correctly assess patient symptom severity in gastrooesophageal reflux disease? Aliment Pharmacol Ther 2004; 20: 1161-9.
42. Slevin ML, Plant H, Lynch D, et al. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988; 57: 109-12.
43. Cohen J. Statistical power analysis for the behavioural sciences. New York: Academy Press, 1977.
44. Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127: 1329-37.
45. Veldhuyzen Van Zanten SJ, Chiba N, Armstrong D, et al. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol 2005; 100: 1489-90.
46. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 1055-65.
47. Tack J, Caenepeel P, Arts J, et al. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut 2005; 54: 1370-6.